Sumitomo Pharma Co., Ltd. Logo

Sumitomo Pharma Co., Ltd.

R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.

4506 | T

Overview

Corporate Details

ISIN(s):
JP3495000006
LEI:
Country:
Japan
Address:
大阪市中央区道修町2丁目6番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sumitomo Pharma Co., Ltd. is a research and development-oriented pharmaceutical company focused on creating innovative medicines and healthcare solutions. The company concentrates its R&D and commercial activities in the therapeutic areas of oncology, psychiatry, and neurology. It develops treatments across various modalities, including small molecules, regenerative medicine, and cell therapy. Sumitomo Pharma operates with global business platforms, with a strategic focus on Japan and the United States as its primary markets. The company's mission is to contribute to the betterment of healthcare and fuller lives for people worldwide by translating scientific innovation into real-world solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 08:19
Registration Form
確認書
Japanese 8.7 KB
2025-11-04 08:13
Interim Report
半期報告書-第206期(2025/04/01-2025/09/30)
Japanese 319.2 KB
2025-10-31 08:39
M&A Activity
訂正臨時報告書
Japanese 41.0 KB
2025-06-27 09:05
Post-Annual General Meeting Information
臨時報告書
Japanese 29.6 KB
2025-06-26 09:39
Registration Form
確認書
Japanese 8.7 KB
2025-06-26 09:36
Governance Information
内部統制報告書-第205期(2024/04/01-2025/03/31)
Japanese 24.0 KB
2025-06-26 09:31
Annual Report
有価証券報告書-第205期(2024/04/01-2025/03/31)
Japanese 2.1 MB
2025-05-30 09:41
M&A Activity
訂正臨時報告書
Japanese 40.7 KB
2025-05-14 09:18
M&A Activity
訂正臨時報告書
Japanese 36.6 KB
2025-04-28 10:06
Regulatory News Service
訂正臨時報告書
Japanese 24.3 KB
2025-04-28 10:03
Regulatory News Service
臨時報告書
Japanese 19.0 KB
2025-04-03 09:39
M&A Activity
臨時報告書
Japanese 41.7 KB
2025-01-31 08:11
Regulatory News Service
臨時報告書
Japanese 18.7 KB
2024-12-19 07:19
Regulatory News Service
臨時報告書
Japanese 19.2 KB
2024-11-01 03:30
Interim Report
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Sumitomo Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sumitomo Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sumitomo Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Medios AG Logo
Compounding patient-specific therapies and supplying specialty pharma for complex conditions.
Germany
ILM1
Develops cord blood stem cell therapies for osteoarthritis & infant lung disease, plus banking.
South Korea
078160
MediWound Ltd. Logo
Develops enzymatic therapies for non-surgical tissue repair in burns and chronic wounds.
United States of America
MDWD
Medizen Humancare Inc Co., Ltd Logo
Offers DTC genetic testing and genomic analysis for personalized disease risk prediction.
South Korea
236340
Medy-Tox Inc. Logo
Develops and markets botulinum toxins and dermal fillers for global aesthetic & therapeutic use.
South Korea
086900
MeiraGTx Holdings plc Logo
Develops genetic medicines for eye, salivary gland, and CNS disorders using gene regulation tech.
United States of America
MGTX
Meito  Sangyo  Co., Ltd. Logo
Produces food products and specialty chemicals for industrial and pharmaceutical applications.
Japan
2207
Merck & Co., Inc. Logo
A global biopharma developing innovative medicines, vaccines, and animal health products.
United States of America
MRK
Mereo BioPharma Group plc Logo
A clinical-stage biopharma developing and commercializing novel therapies for rare diseases.
United States of America
MREO
Mersana Therapeutics, Inc. Logo
Developing innovative antibody-drug conjugates using proprietary platforms to treat cancer.
United States of America
MRSN

Talk to a Data Expert

Have a question? We'll get back to you promptly.